Virios Therapeutics, Inc. (VIRI)
Market Cap | 6.50M |
Revenue (ttm) | n/a |
Net Income (ttm) | -5.07M |
Shares Out | 27.76M |
EPS (ttm) | -0.26 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 629,108 |
Open | 0.218 |
Previous Close | 0.222 |
Day's Range | 0.218 - 0.238 |
52-Week Range | 0.156 - 2.420 |
Beta | 1.62 |
Analysts | Strong Buy |
Price Target | 1.00 (+327.35%) |
Earnings Date | Aug 8, 2024 |
About VIRI
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly kn... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for VIRI stock is "Strong Buy" and the 12-month stock price forecast is $1.0.
News
![](https://cdn.snapi.dev/images/v1/n/v/press3-2444071.jpg)
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antivi...
![](https://cdn.snapi.dev/images/v1/o/t/press10-2438954.jpg)
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antivi...
![](https://cdn.snapi.dev/images/v1/s/k/press18-2437996.jpg)
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antivi...
![](https://cdn.snapi.dev/images/v1/h/9/press6-2420604.jpg)
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 -
![](https://cdn.snapi.dev/images/v1/1/x/conf12-2406229.jpg)
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat de...
![](https://cdn.snapi.dev/images/v1/f/q/press12-2341883.jpg)
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reacti...
![](https://cdn.snapi.dev/images/v1/y/0/press11-2301204.jpg)
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat d...
![](https://cdn.snapi.dev/images/v1/j/v/press6-2298581.jpg)
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to tr...
![](https://cdn.snapi.dev/images/v1/z/y/press10-2238316.jpg)
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 - - Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 -
![](https://cdn.snapi.dev/images/v1/1/o/press4-2212908.jpg)
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to treat...
![](https://cdn.snapi.dev/images/v1/t/q/press7-2154188.jpg)
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on adva...
![](https://cdn.snapi.dev/images/v1/1/n/conf6-2141134.jpg)
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapi...
![](https://cdn.snapi.dev/images/v1/k/1/conf3-2100318.jpg)
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat d...
![](https://cdn.snapi.dev/images/v1/k/w/press4-2066924.jpg)
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat ...
![](https://cdn.snapi.dev/images/v1/k/t/conf6-2059063.jpg)
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat ...
![](https://cdn.snapi.dev/images/v1/y/g/press19-2021216.jpg)
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
ATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat d...
![](https://cdn.snapi.dev/images/v1/k/s/press13-2016774.jpg)
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Continued Progress in Expanding and Advancing Clinical Pipeline - - Conference Call Today at 8:30 a.m. ET -
![](https://cdn.snapi.dev/images/v1/y/k/press3-2014331.jpg)
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat d...
![](https://cdn.snapi.dev/images/v1/v/o/press6-1973519.jpg)
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat d...
![](https://cdn.snapi.dev/images/v1/w/t/press6-1908383.jpg)
Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
ATLANTA, May 25, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the...
![](https://cdn.snapi.dev/images/v1/k/o/press7-1889570.jpg)
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat de...
![](https://cdn.snapi.dev/images/v1/o/9/press20-1884661.jpg)
Virios Therapeutics Announces First Quarter 2023 Financial Results
ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat de...
![](https://cdn.snapi.dev/images/v1/h/i/conf6-1870968.jpg)
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral the...
![](https://cdn.snapi.dev/images/v1/a/r/press4-1850884.jpg)
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
-Virios' IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program Results-
![](https://cdn.snapi.dev/images/v1/o/z/press7-1795420.jpg)
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat ...